Cancer Cases Among Trans People Could Double in Decade, Study Warns

Queen Mary University of London

A study led by Queen Mary University of London has found that the number of new cancer cases each year among transgender and gender-diverse people in England could more than double over the next decade.

The research published in eClinicalMedicine , estimates that approximately 965 new cancer cases occur annually among transgender and gender-diverse people in England. This figure is projected to rise to around 1,739 cases in five years and 2,257 cases within 10 years.

The researchers indicate that the findings highlight the need for cancer services to prepare for the changing needs of this populations, alongside improvements in cancer screening, healthcare professional training and the collection of patient data.

The study, believed to be the first to estimate the annual number of cancer cases among transgender and gender-diverse people in England, combined national cancer statistics, population data and existing research on the potential effects of gender-affirming healthcare.

Breast cancer was estimated to be the most common cancer in this population, accounting for approximately 19 per cent of cases, followed by colorectal cancer, 12 per cent and lung cancer, 11 per cent.

Despite growing recognition of the healthcare needs of transgender and gender-diverse people, reliable national data on cancer incidence in this population remain limited.

Current cancer registration systems do not consistently distinguish between sex characteristics and gender identity, making it difficult to accurately understand cancer patterns and plan appropriate services.

Transgender and gender-diverse people may also face barriers to cancer screening and treatment, including concerns about discrimination, healthcare environments that do not met their needs, and uncertainty about eligibility for screening programmes.

Potential impact of gender-affirming care

The researchers also examined how access to gender-affirming care, including hormone treatment and surgery, could influence future cancer cases.

Their modelling suggests that if transgender and gender-diverse people were able to access the gender-affirming they planned to receive, the projected number of annual cancer cases in 10 years could be approximately 11 per cent lower, falling to 2,006.

This is because different types of gender-affirming care have previously been found to affect the likelihood of developing certain cancers, with a reduction in breast cancer among trans men, prostate cancer among trans women, and ovarian, uterine and cervical cancers following relevant surgeries.

Breast cancer has been shown to be more common among trans women receiving feminising hormone therapy but the incidence is still lower than for cisgender women.

The researchers stress that these findings are based on estimates and modelling rather than directly observed outcomes.

Dr Alison Berner, lead author of the study and Clinical Senior Lecturer in Medical Oncology at Queen Mary, said: "Our research suggests that the number of cancer cases among transgender and gender-diverse people in England could more than double over the next decade. This highlights an important and often overlooked area of cancer care. As this population ages, we need to ensure cancer services are prepared to meet patients' needs and that everyone can access appropriate screening diagnosis and treatment."

Dr Chloe Pasin, co-lead author and postdoctoral researcher at Queen Mary, said: "Cancer care is not one-size-fits-all. Our findings suggest that gender-affirming treatments could reduce the likelihood of developing some cancers, while potentially increasing the risk of others. Understanding these differences is essential to care. But we also need better data to build a clearer picture of cancer risks among transgender and gender-diverse people and make sure their needs are not overlooked."

The study team hope that these findings will help inform future cancer service planning, workforce training and screening policies, and highlight the need for more nuanced data collection in healthcare.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.